A pH-responsive T<sub>1</sub>-T<sub>2</sub> dual-modal MRI contrast agent for cancer imaging.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 36572677.
- Also identified by DOI 10.1038/s41467-022-35655-x and PMC identifier 9792454.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Magnetic resonance imaging (MRI) is a non-invasive imaging technology to diagnose health conditions, showing the weakness of low sensitivity. Herein, we synthesize a contrast agent, SPIO@SiO<sub>2</sub>@MnO<sub>2</sub>, which shows decreased T<sub>1</sub> and T<sub>2</sub> contrast intensity in normal physiological conditions. In the acid environment of tumor or inflamed tissue, the manganese dioxide (MnO<sub>2</sub>) layer decomposes into magnetically active Mn<sup>2+</sup> (T<sub>1</sub>-weighted), and the T<sub>1</sub> and T<sub>2</sub> signals are sequentially recovered. In addition, both constrast quenching-activation degrees of T<sub>1</sub> and T<sub>2</sub> images can be accurately regulated by the silicon dioxide (SiO<sub>2</sub>) intermediate layer between superparamagnetic iron oxide (SPIO) and MnO<sub>2</sub>. Through the "dual-contrast enhanced subtraction" imaging processing technique, the contrast sensitivity of this MRI contrast agent is enhanced to a 12.3-time difference between diseased and normal tissue. Consequently, SPIO@SiO<sub>2</sub>@MnO<sub>2</sub> is successfully applied to trace the tiny liver metastases of approximately 0.5 mm and monitor tissue inflammation.
Medical subject headings
- Contrast Media
- Liver Neoplasms